Fragmento

To the editor: Once considered irreversible, there are well-documented cases of reversibility of liver cirrhosis, which has stimulated evaluation of antifibrotic drugs such as pirfenidone. Recently, the European Medicine Agency granted authorization to commercialize pirfenidone for patients with idiopathic pulmonary fibrosis (IPF) based on evidence confirming its safety and efficacy. Long term pirfenidone administration (2,400 mg/day) has been evaluated in 789 patients with IPF. Median duration of exposure was 2.6 years (1 week-7.7 years). Adverse events tended to occur early, were almost always mild to moderate in severity, and rarely led to treatment discontinuation. In the Mexican market, a 600 mg, slow release formulation is available to reduce adverse events. Clinical trials are underway to continue evaluating this promising drug in liver disease.

Palabras clave:

2014-10-30   |   431 visitas   |   Evalua este artículo 0 valoraciones

Vol. 13 Núm.6. Noviembre-Diciembre 2014 Pags. 845-846 Ann Hepatol 2014; 13(6)